Similarly, knocking out of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) (targets of palbociclib or ibrancein in breast cancer), ERBB2 (target of trastuzumab in breast cancer), Bruton’s tyrosine kinase (BTK) (target of ibrutinib or imbruvica in hematopoietic cancer), CRBN (target of lenalidomide or revlimid in skin cancer), and CYP17A1 (target of abiraterone acetate or zytiga in prostate cancer) did not influence the fitness of cancer cell lines (Figure 2D). The gene discussed is ERBB2; the disease is hematopoietic and lymphoid cell neoplasm.